CytoPherx is a portfolio company of Apjohn Ventures, based in Kalamazoo, MI, which participated in the round led by Diamond Capital Partners in Los Angeles. Also participating was Lurie Investments of Chicago. Previous investor North Coast Technology Ventures of Ann Arbor and Midland, MI, did not appear to take part in the latest round, according to VentureWire.
A University of Michigan spinout, CytoPherx is developing a hollow-fiber dialysis filter to treat conditions like renal failure and inflammation caused by bypass surgery. The filter sequesters and deactivates leukocytes in the patient’s blood system. Acute renal failure and end-stage renal disease are the company’s initial targets, followed by inflammation caused by cardiopulmonary bypass surgery.